Pre-made Racotumomab benchmark antibody ( Whole mAb, anti-Idiotope of anti-NeuGc-ganliosides therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Racotumomab biosimilar, Whole Mab: Anti-Idiotope of Anti-NeuGc-ganliosides therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Racotumomab (trade name Vaxira) is a therapeutic cancer vaccine for the treatment of solid tumors that is currently under clinical development by Recombio, an international public-private consortium with the participation of the Center of Molecular Immunology at Havana, Cuba (CIM) and researchers from Buenos Aires University and National University of Quilmes in Argentina. It induces the patient's immune system to generate a response against a cancer-specific molecular target with the purpose of blocking tumor growth, slowing disease progression and ultimately increasing patient survival.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-463-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Racotumomab biosimilar, Whole Mab: Anti-Idiotope of Anti-NeuGc-ganliosides therapeutic antibody
INN Name	Racotumomab
Target	Idiotope of anti-NeuGc-ganliosides
Format	Whole mAb
Derivation	Mouse
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2008
Year Recommended	2009
Companies	Center of Molecular Immunology;Elea;Innogene Kalbiotech;Recombio
Conditions Approved	Non-small cell lung cancer
Conditions Active	Neuroblastoma
Conditions Discontinued	Breast cancer;Colorectal cancer;Malignant melanoma;Small cell lung cancer;Solid tumours
Development Tech	na